AzTrials
AzTrials

AsthmaPhase 2NCT02794519

A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma

A Phase 2 study testing Sirukumab and Rescue medication in people with Asthma, run by GlaxoSmithKline at 8 sites in 2 countries.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

Sirukumab is a fully human anti interleukin (IL)-6 immunoglobulin G1-kappa monoclonal antibody (MAb) which is in development for the treatment of rheumatoid arthritis (RA). The continuing unmet need in subjects with asthma refractory to corticosteroid therapy and increased understanding of asthma pathogenesis have… Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Asthma
What is being tested?
Sirukumab and Rescue medication
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
0 participants
Where
8 sitesin 2 countries
Study dates
23 Sep 2016to 4 Oct 2016
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subjects aged 18 - 75 years, inclusive.
  • Severe, uncontrolled asthma according to the following criteria: Physician-diagnosed asthma for >=12 months, and; treatment for at least 3 months with >=880 microgram per day of fluticasone propionate (FP) dry powder for inhalation (DPI) or its equivalent, plus a long acting beta agonist (LABA), and' ACQ-7 score >=1.5, and; a documented history (e.g., medical record verification) in the 12 months prior to Visit 2 of >=1 exacerbation resulting in prescription for systemic oral corticosteroids or hospitalisation or extended observation in a hospital emergency room or outpatient centre. [For subjects on maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days is required] and; pre-bronchodilator FEV1 35-80% inclusive, with evidence of >=12% (and 200 milliliter [mL]) reversibility in FEV1 measured 15-30 minutes following 4 actuations of salbutamol (100 microgram per actuation) or albuterol (90 microgram per actuation) via pre-metered dose inhaler (pMDI). This reversibility criterion should have been documented in the 12-months prior to Screening. If no prior data are available this should be demonstrated either at Screening (Visit 2) or at the Randomization visit (Visit 3); blood eosinophil count <300 cells per microliter at screening.
  • Body mass index 18-45 kilogram per meter square.
  • Male or Females and Male subjects with female partners of child bearing potential must comply with the following contraception requirements from the time of first dose of study medication until a cycle of spermatogenesis following five terminal half- lives after the last dose of study medication: Vasectomy with documentation of azoospermia; Male condom plus partner use of one of the following contraceptive options: Contraceptive subdermal implant; Intrauterine device or intrauterine system; Combined estrogen and progestogen oral contraceptive; Injectable progesterone; Contraceptive vaginal ring; Percutaneous contraceptive patches.
  • This is an all-inclusive list of those methods that meet the following GlaxoSmithKline (GSK) definition of highly effective: having a failure rate of less than 1% per year when used consistently and correctly and, when applicable, in accordance with the product label. For non-product methods (e.g., male sterility), the investigator determines what is consistent and correct use. The GSK definition is based on the definition provided by The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH).
  • The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.
  • A female subject is eligible to participate if she is of non-child bearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as age greater than 60 or 12 months of spontaneous amenorrhea with an appropriate clinical profile [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) >40 milliinternational units per milliliter (MlU/mL) and estradiol <40 picogram per milliliter (pg/mL) (<140 picomole per liter [pmol/L] is confirmatory) or if of child-bearing potential is using a highly effective method for avoidance of pregnancy for the duration of dosing and until 4 months post last-dose.
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Who cannot join

  • Presence of a known pre-existing, clinically important lung condition other than asthma. This includes chronic obstructive pulmonary disease (COPD), bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or a history of lung cancer.
  • Lower respiratory tract infection (LRTI) or asthma exacerbation requiring antibiotics or systemic corticosteroids within 6 weeks of screening.
  • Evidence of respiratory infection at screening.
  • Has a history of chronic or recurrent infectious disease or ongoing infection including, but not limited to, chronic renal infection, chronic chest infection, recurrent urinary tract infection (example, recurrent pyelonephritis, chronic non-remitting cystitis), or open, draining skin wound or an ulcer.
  • Serious infection within 8 weeks of enrolment, including, but not limited to hepatitis, pneumonia, sepsis, or pyelonephritis; or has been hospitalized for an infection; or has been treated with intravenous (IV) antibiotics for an infection, within 8 weeks prior to the first administration of study drug.
  • Opportunistic infection, example, a nontuberculous mycobacterial infection or cytomegalovirus, pneumocystosis, aspergillosis within 6 months prior to screening.
Show all 30Show fewer
  • Evidence of poorly controlled chronic medical conditions other than asthma, example, subjects with known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, and haematological or any other system abnormalities that are uncontrolled with standard treatment.
  • Current history of suicidal ideation or a past history of suicide attempt.
  • Lactating, pregnant, or planning to become pregnant during the study.
  • Malignancy within 5 years (except local basal cell carcinoma, or fully excised local dermal, squamous cell carcinoma).
  • Has a history of known demyelinating diseases such as multiple sclerosis or optic neuritis.
  • Has a history of gastrointestinal perforation or currently has active diverticulitis.
  • QTcorrected (QTc) >450 milliseconds (msec) or QTc >480 msec in subjects with Bundle Branch Block. Notes: The QTc is the QT interval corrected for heart rate according to Bazett's formula (QTcB), Fridericia's formula (QTcF), and/or another method, machine-read or manually over-read; The specific formula that will be used to determine eligibility and discontinuation for an individual subject should be determined prior to initiation of the study. In other words, several different formulae cannot be used to calculate the QTc for an individual subject and then the lowest QTc value used to include or discontinue the subject from the trial.
  • Alanine transaminase (ALT) >1.5 times upper limit of normal (ULN) and bilirubin >ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
  • Laboratory abnormalities: Neutrophils <1.95 multiplied by 10 raise to 9 per liter; Platelet count <140 multiplied by 10 raise to 9 per liter; Hemoglobin <8.5 grams per decilitre (g/dL); WBC count <3.5 × multiplied by 10 raise to 9 per liter.
  • Use of systemic corticosteroids within 6 weeks of screening. The only exception is subjects who take <=10 mg prednisolone (or equivalent) orally per day for chronic maintenance therapy, and who have been maintained on this regimen for >=12 weeks.
  • The subject has received an investigational drug within 30 days or 5-half-lives (whichever is longer) prior to the first dose of study drug.
  • Use of other monoclonal antibodies within 3 months (or 130 days in the case of Xolair) of screening.
  • Live virus or bacterial vaccine from 30 days before screening.
  • Immunomodulatory/suppressive agents including but not limited to cyclophosphamide, a cytotoxic agent, cyclosporine A, azathioprine, tacrolimus, mycophenolate mofetil, oral or parenteral gold, or D-penicillamine within 3 months of screening.
  • Bronchial thermoplasty within 12 months of screening.
  • Subjects with a smoking history of >=10 pack years (pack years = number of cigarettes smoked per day divided by 20 into number of years smoked). Note: Subjects who are current smokers, or ex-smokers (having given up smoking for >=6 months), are eligible for the study if their smoking history is <10 pack years.
  • History of alcohol or illegal substance abuse consumption within 2 years of the study start.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation. Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (example, compromise the well-being) of the subject or that could prevent, limit, or confound the protocol-specified assessments.
  • Is an employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator.
  • Chest X-Ray (CXR) within 6 months of screening showing evidence of active or inactive tuberculosis (TB), or other clinically significant disease other than asthma. If a CXR is not available, it must be performed at screening.
  • Positive for Mycobacterium tuberculosis using QuantiFERON Gold test at screening.
  • Human Immunodeficiency Virus (HIV) positive or determined to be HIV positive at screening, testing to be conducted in accordance with local practice.
  • Presence of hepatitis B surface antigen (HBsAg) or core antigen (HBcAg). Subjects who are HBsAg negative, but hepatitis core antigen positive may be included if they are polymerase chain reaction (PCR) negative for Hepatitis B deoxyribonucleic acid (DNA).
  • Positive hepatitis C (Hep C) test result at screening or within 3 months prior to first dose of study treatment.

Trial locations and contacts

8 sites in 2 countries.

8 sites in 2 countries

United States5 sites

  • GSK Investigational Site

    Aventura, Florida, 33180

  • GSK Investigational Site

    Cincinnati, Ohio, 45231

  • GSK Investigational Site

    Long Beach, California, 90808

  • GSK Investigational Site

    Richmond, Virginia, 23225

  • GSK Investigational Site

    Richmond, Virginia, 23229

Other trials in United States

Spain3 sites

  • GSK Investigational Site

    Alcorcón (Madrid), 28922

  • GSK Investigational Site

    Girona, 17005

  • GSK Investigational Site

    Santiago de Compostela. La Coruña., 15706

Other trials in Spain

About this study

Official title: 205076: A Phase II, Multicenter, Randomized, Double-blind (Sponsor-unblind), Placebo- Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of Sirukumab in Subjects With Severe, Poorly Controlled Asthma

Sirukumab is a fully human anti interleukin (IL)-6 immunoglobulin G1-kappa monoclonal antibody (MAb) which is in development for the treatment of rheumatoid arthritis (RA). The continuing unmet need in subjects with asthma refractory to corticosteroid therapy and increased understanding of asthma pathogenesis have stimulated the development of targeted biologics based on predictive biomarkers. The majority of approaches to date have targeted T Helper 2 (Th2) cytokines or their downstream effects. Targeting IL-6 in severe asthma represents an unprecedented approach that has potential to address non-Th2 drivers of severe asthma. This multicenter, randomized, double-blind (sponsor-unblind), placebo-controlled, parallel group study will investigate the efficacy of sirukumab compared to placebo in subjects having uncontrolled severe asthma despite use of high dose inhaled corticosteroid (ICS) in combination with long-acting Beta-agonist (LABA). The study will employ a variable treatment period for individual subjects. Dosing will continue every 4 weeks until week 44 (inclusive), or until 24 weeks after the final subject has been randomized, whichever the sooner. Upon receiving the final dose of study medicine or placebo, subjects will enter a 16 week Follow Up period. Overall, the duration of participation for subjects who complete the full 44-week treatment period and Follow Up period may be up to 64 weeks. Approximately 175 subjects will be randomized such that 140 evaluable subjects complete the study.

Conditions
Asthma
Being tested
Sirukumab, Placebo, Rescue medication
Keywords
Asthma Control Questionnaire, interleukin-6, Sirukumab, severe, poorly controlled asthma, asthma, ACQ
Medical subject headings
Asthma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SirukumabDrug

    This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.

  • PlaceboDrug

    This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.

  • Rescue medicationDrug

    Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.

Study groups in NCT02794519
Study groupRoleWhat they receive
Sirukumab 50 mg/mL administered subcutaneously every 4 weeksExperimentalSubjects will receive sirukumab 50 milligram/milliliter (mg/mL) subcutaneously every 4 weeks. They will receive the treatment for minimum of 20 weeks but up to 44 weeks of dosing. Sirukumab will be administered by the trained site staff at Baseline, Weeks 4 and Week 8. From the Week 12 visit onwards, subjects may start to self-administer study drug at the site under the supervision of the trained site staff if they are able and willing to do so. If not, study drug will continue to be administered by the trained site staff.
Receives: Drug: Sirukumab; Drug: Rescue medication
Placebo administered subcutaneously every 4 weeksPlacebo comparatorSubjects will receive placebo subcutaneously every 4 weeks. They will receive the treatment for minimum of 20 weeks but up to 44 weeks of dosing. Placebo will be administered by the trained site staff at Baseline, Weeks 4 and Week 8. From the Week 12 visit onwards, subjects may start to self-administer study drug at the site under the supervision of the trained site staff if they are able and willing to do so. If not, study drug will continue to be administered by the trained site staff.
Receives: Drug: Placebo; Drug: Rescue medication

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from Baseline in Asthma Control Questionnaire-7 (ACQ-7) at Week 24

    The ACQ-7 is a seven-item questionnaire that is a measure of a subject's asthma control. Six of the questions will be self-completed by the subject, recalling over the previous 7 days. The six questions enquire about the frequency and/or severity of symptoms (nocturnal awakening, activity limitation, shortness of breath and wheeze), and rescue bronchodilator use. The response options for all these questions consist of a zero (no impairment/limitation) to six (total impairment/ limitation) scale. The final question is a rating of forced expiratory volume in 1 second FEV1% predicted. The questions are equally weighted and the ACQ score is the mean of the 7 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled). Baseline value is the value obtained at Day 1 before administration of investigational product (IP). Change from baseline in ACQ-7 score will be analysed using a Bayesian repeated measures model.

    Measured: Baseline and Week 24

Secondary outcomes (20)

  1. Safety as assessed by number of subjects with adverse events (AE) and serious adverse events (SAE)

    AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgement.

    Measured: Up to 60 Weeks

  2. Safety as assessed by body temperature

    Body temperature will be measured in semi-supine position after 5 minutes rest.

    Measured: Up to 60 Weeks

  3. Safety as assessed by systolic and diastolic blood pressure

    Blood pressure will be measured in semi-supine position after 5 minutes rest.

    Measured: Up to 60 Weeks

  4. Safety as assessed by pulse rate

    Pulse rate will be measured in semi-supine position after 5 minutes rest.

    Measured: Up to 60 Weeks

  5. Safety as assessed by electrocardiogram (ECG)

    Centralized 12-lead ECG will be performed in triplicate at baseline and singly thereafter. ECG will also be performed when clinically indicated. ECG measurements will be made after the subject has rested in the supine position for 5 minutes. The ECG will be obtained after the vital signs assessments but before lung function testing followed by other study procedures. Collection shortly after a meal or during sleep will be avoided since QT prolongation can occur at these times.

    Measured: Up to 60 Weeks

  6. Safety as assessed by number of subjects with abnormal hematology parameters

    Hematology will include hemoglobin, hematocrit, red blood cells (RBC) count, white blood cells (WBC) count, absolute neutrophils, neutrophils segmented percentage with differential, neutrophils bands percentage, basophils percentage, eosinophils percentage, absolute eosinophils, lymphocytes percentage, monocytes percentage, platelet count.

    Measured: Up to 48 Weeks

  7. Safety assessed by serum chemistry

    Serum chemistry will include potassium, chloride, sodium, calcium, blood Urea nitrogen (BUN), creatinine, glucose, aspartate transaminase (SGOT), alanine transaminase (SGPT), alkaline phosphatise, phosphate, albumin, total protein, direct, indirect and total bilirubin.

    Measured: Up to 48 Weeks

  8. Safety assessed by lipid profile

    Lipid profile will include total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides.

    Measured: Up to 48 Weeks

  9. Change from baseline in ACQ-7 during the treatment period

    The ACQ-7 is a seven-item questionnaire that is as a measure of a subject's asthma control.

    Measured: Baseline and Up to 48 Weeks

  10. Change from baseline in ACQ-5 during the treatment period

    The ACQ-5 is a five-item questionnaire that is as a measure of a subject's asthma control. The five ACQ-5 questions are scored on a 7-point scale (0 = good control, 7 = poor control), and the overall score is the mean of the five responses. Baseline value is the value obtained at Day 1 before administration of investigational product (IP). Change from baseline in ACQ-5 score will be analysed using a Bayesian repeated measures model.

    Measured: Baseline and Up to 48 Weeks

  11. Number of subjects who achieve an ACQ-7 response

    The ACQ-7 is a seven-item questionnaire that is as a measure of a subject's asthma control.

    Measured: Up to 48 Weeks

  12. Change from baseline in pre-bronchodilator FEV1 during the treatment period

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Baseline value is the value obtained at Day 1 before administration of IP. Change from Baseline is the difference between the value at Indicated visit and value at Baseline.

    Measured: Baseline and Up to 48 Weeks

  13. Change from baseline in average morning peak expiratory flow rate (PEFR)

    PEFR is the maximum flow rate generated during a forceful exhalation, starting from full lung inflation. Baseline value is the value obtained at Day 1 before administration of IP. Change from Baseline is the difference between the value at Indicated visit and value at Baseline.

    Measured: Baseline and Up to 48 Weeks

  14. Change from baseline in St. George's Respiratory Questionnaire (SGRQ)

    The SGRQ comprises 50 questions designed to measure health status (quality of life) in subjects with diseases of airways obstruction. The SGRQ includes a total score and three domain scores: Symptoms, Activity and Impacts (Psycho-social) as well as a total score. A minimum change in score of 4 units is considered to be established as clinically relevant. A one month recall period shall be used for assessment of the SGRQ. Baseline value is the value obtained at Day 1 before administration of IP. Change from Baseline is the difference between the value at Indicated visit and value at Baseline.

    Measured: Baseline and Up to 48 Weeks

  15. Number of subjects who achieve SGRQ response

    The SGRQ comprises 50 questions designed to measure health status (quality of life) in subjects with diseases of airways obstruction.

    Measured: Up to 48 Weeks

  16. Change from baseline in daily salbutamol/albuterol use

    Subjects will complete the Asthma Daily Symptom Diary (ADSD), a novel asthma symptom diary and record daily use of rescue medication (salbutamol/albuterol) via an electronic diary. Baseline value is the value obtained at Day 1 before administration of IP. Change from Baseline is the difference between the value at Indicated visit and value at Baseline.

    Measured: Baseline and Up to 48 Weeks

  17. Annualized rate of severe asthma exacerbations during the treatment period

    Severe asthma exacerbations are defined as worsening of asthma which requires use of systemic corticosteroids and/or hospitalisation and/or Emergency Department (ED) visits.

    Measured: Baseline and Up to 48 Weeks

  18. Assessment of pharmacokinetics (PK) of sirukumab

    Serum concentrations of sirukumab and derived population PK parameters will be evaluated. Blood samples for PK analyses of sirukumab serum concentrations will be drawn prior to the administration of study drug.

    Measured: Blood sample for PK analysis would be collected at Baseline, Week 1, Week 4, Week 8, Week 12, Week 24, Week 48, Week 54 and Early Withdrawal/Week 60.

  19. Change from baseline in blood or serum pharmacodynamic (PD) biomarkers including but not limited to interleukin (IL)-6 and C-reactive protein (CRP)

    Baseline value is the value obtained at Day 1 before administration of investigational product (IP). Change from Baseline is the difference between the value at Indicated visit and value at Baseline.

    Measured: Blood sample for analysis of PD biomarkers would be collected at Baseline, Week 1, Week 4, Week 8, Week 12, Week 24, Week 48, Week 54 and Early Withdrawal/Week 60.

  20. Incidence and titres of serum anti-sirukumab antibodies post-dosing

    Analysis of anti-sirukumab antibodies will be performed using validated bioanalytical assays.

    Measured: Blood sample for testing antibodies against sirukumab would be collected at Baseline, Week 12, Week 24, Week 48 and Early Withdrawal/Week 60.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jun 2016 (estimated)
  2. Study start23 Sep 2016
  3. Primary completion4 Oct 2016
  4. Study completion4 Oct 2016 (estimated)

Why it stopped: This study has suspended participant recruitment.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02794519
Sponsor's protocol ID
205076
Status last verified
Aug 2018
First submitted
6 Jun 2016
Last updated
31 Aug 2018
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Sirukumab and Rescue medication in people with Asthma, run by GlaxoSmithKline at 8 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 31 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in United States, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from Baseline in Asthma Control Questionnaire-7 (ACQ-7) at Week 24 (time frame: Baseline and Week 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02794519.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2018; AzTrials last refreshed its copy on 6 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in